Research progress of anti-acute marrow leukemia drugs by targeting FLT3 / 药学学报

Acute myeloid leukemia (AML) is a genetic heterogeneous disease in which primordial and juvenile myeloid cells proliferate or accumulate abnormally in bone marrow, peripheral blood and other tissues, resulting in damage to normal hematopoietic function. Studies have shown that about 30% of AML patients have FMS-like tyrosine kinase 3 (FLT3), FLT3 abnormal regulation is closely related to the occurrence and development of AML. At present, FLT3 has become an important target for developing small molecular targeted drugs. Currently, a variety of FLT3 inhibitors and FLT3 degraders have been developed targeting FLT3, and some compounds have exhibited good anti-AML activity. This article summarizes and sorts out the current mainstream drugs for AML therapeutic targeting FLT3, in order to provide a reference for the development and design of AML drugs.

Advances in the research of FLT3 inhibitors for acute myeloid leukemia / 中国药科大学学报

@#Acute myeloid leukemia(AML)is one of the most common acute leukemias in adults. Those patients with FLT3 mutations have a particularly poor prognosis. Recently, the emergence of a variety of targeted inhibitors has shown the capability of suppressing FLT3 signaling in vivo, which provided a new way to treat AML. In this paper, we reviewed those inhibitors based on their structures, which include indolone-related inhibitors, indolocarbazo-related inhibitors, benzimidazole/benzopyrazole-related inhibitors, quinoline/quinoxaline/quinazoline-related inhibitors, tricyclic inhibitors, pyrimidine-related inhibitors and others.